An examination of potential implications for how drug manufacturers manage their portfolios in the wake of the Inflation Reduction Act
Within healthcare, the Inflation Reduction Act (IRA) aims to improve affordability and accessibility by lowering prescription drug prices and out-of-pocket costs for Medicare beneficiaries and extending premium subsidies in the Affordable Care Act’s (ACA) marketplaces.
Sweeping proposals introduced by the act represent some of the most significant healthcare legislation since the ACA by giving Medicare the ability to negotiate drug prices with manufacturers. In this paper, we discuss potential implications of these policies for how drug manufacturers manage their portfolios.
Inflation Reduction Act impact on biopharma portfolio strategies
Download PDFKPMG Deal Advisory distributes a wide selection of thought leadership that highlights the latest M&A issues and trends.
Industry insights and trends, one click away.